EVALUATION OF ANTIDEPRESSANT ACTIVITY OF DIPHENHYDRAMINE IN MICE.
Objective: The study aims to evaluate the antidepressant activity of different doses of diphenhydramine in mice at (0.5, 1, 2 mg /Kg, IP). Materials and Methods: The mice were divided into 5 groups for each testing methods, each group consist of five animals. Group 1 served as a control and was given normal saline 0.9% (5ml/kg,IP), group 2 received (20 mg /Kg, IP) fluoxetine as a standard control. Group 3, 4, 5 were treated with three different doses of diphenhydramine (0.5, 1, 2 mg /Kg, IP) respectively. The normal behaviors of each group of mice were evaluated after 30 min. of drug administration. The test was used to evaluate the antidepressant activity of diphenhydramine in Open Field, Modified Forced Swimming Test and Tail Suspension Test. Results: It is found that the increase in the locomotor activity in open field cage by increasing the number of square cross to (94.2Â±28.7) (93.2Â±25.6) (86.6Â±22.1) respectively according to the doses of diphenhydramine in comparison with control group (69.4Â±27.2) at p< 0.05. In modified forced swimming test, the result also showed that the administration of diphenhydramine at (0.5, 1, 2 mg /Kg, IP) were reduced the immobility time (68.8 Â± 21.1) (56.4 Â± 17.7) (47.6 Â± 21.7) Sec. respectively in comparison with control group. In the present study, It is found that the administration of diphenhydramine at (0.5, 1, 2 mg /Kg,IP) were significantly increased in the swimming time (143.2 Â± 16.2) (152.6 Â± 18.7) (160.02 Â± 15.5) Sec. Sec. in comparison with control group (28.8 Â± 3.4) Sec. Conclusion: Thus, this study suggested that the administration of diphenhydramine is produced a good therapy used in the treatment of depressed patients without side effect .
Key words: Antidepressant, Tail suspended test, Open failed test, Diphenhydramine, Force swimming test.Â Â
2. Harvey RA. Clark MA, Finkel,R Rey,JA, Whalen,K Lippincottâ€™s
Illustrated Reviews:Pharmacology. Lippincott Williams & Wilkins, a Wolters Kluwer business. 5th ed. 2012; P. 151-160.
3. Meyers S. Monoaminergic supplements as natural antidepressants. Altern Med Rev 2000; 5:64-71.
4. Jithan A, Chinnalalaiah R. Synthesis and evaluation of antidepressant activity of some curcumin-like compounds. In Pharm Communique . 2009; 2:38-41.
5. Davied. DJ, Samuels.BA, Rainer. Q, Wang. JW, Marsteller. D,Mendez. I, Drew.M , Craig. DA, Gaiard. BP, Guilloux. JP,Artymyshum. RP, Gaiard.AM, Gerald. C, Antonijevie. IR, Leonardo. ED, Hen.R. Neurogenesis-Dependent andâ€“Independed effects of fluoxetine in an Animal model anxiety\ depression. 2009. Neuron. 62, 470-493.
6. Domino, Edward F .History of Modern Psychopharmacology a Personal View with an Emphasis on Antidepressants. Psychosomatic Medicine. 1999; 61: 591-598.
7. Raphael GD, Angello JT, Wu MM, Druce HM. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Annals of allergy, asthma and immunology. 2006; 96 (4): 606â€“14.
8. Yagiela A, Jone Frank J, Dowed, Enid A Neidle. Pharmacology and Therapeutics for Dentistry. 5th ed. 2004; p 272-768.
9. Montoro J, Sastre J, Bartra J, del Cuvillo A, I DÃ¡vila, JÃ¡uregui I . Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol 2006; Vol. 16, Supplement 1: 24-28.
10. Mullol J, AL ValeroBarbier A.J. And Bradbury M.J. Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders. CNS & Neurological Disorders - Drug Targets, 2007, 6, 31-43.
11. Bealer SL, Crowley WR. Stimulation of central and systemic oxytocin release by histamine in the paraventricular hypothalamic nucleus: evidence for an interaction with norepinephrine. Endocrinology 1999; 140: 1158-1164.
12. Leza JC, Lizasoain I, Lorenzo P. Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine - induced hyperactivity. Pharmacol. 1991; 22 (2): 293-6.
13. Brown RE, Steven DR, Haas HL. The physiology of brain histamine. Prog Neurobiol .2001; 63:637-72.
14. Prousky, Jonathan E, Lescheid DW.The role of vitamin B3 and C in the treatment of histadelia. The Journal of orthomolecular Medicine 2002; 17(1) :17-21.
15. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R et al: Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 2004; 20(3):803-810.
16. Lowery CA, Johnsen PL, Hag-Schmidt A, Mikelsen J, Shekhar A. Modulation of anxiety circuits by serotonergic system. Stress 2005; 8:233-246.
17. Moser VC, Mclormick JP, Greason JP, Macphail RC .Comparison of chlordimeform and carbaryl using a functional observational battery Fund Appl. Toxicol. 1988; 11:189-206.
18. Molinengo L and Fundaro A. The effect of chronic atropine administration on mouse motility and on Ach levels in the central nervous system. Pharmacol. Biochem. Behave. 1989; 32:1075-1077.
19. Jintanaporn W, Prasert P, Kittisak S , Supaporn M, Bungorn S. Evaluation of the anxiolytic and antidepressant effects of alcoholic extract of Kaempferia parviflora in aged rats. Am J Agri Bio Sci 2007; 2:94-98.
20. Moallem SA, Hosscinzadeh H, Ghoncheh F. Evaluation of antidepressant effect of aerial parts of Echium vulgare on mice. Iran J Basic Med Sci 2007; 10:189-196.
21. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85:367-370.
22. Vogal GH, Vogel WH. drug discovery and evalution-pharmacological assays. Germany: Springer Publication; 2002. p. 559-61
23. Volkow ND, Gur RC,Wang GJ,Fowler JS. Moberg PJ.Ding YS et al Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155:344-349.
24. Katzung BG, Master SB, Trevor AJ. Basic and clinical pharmacology. 12th ed. Copyright. McGraw â€“ Hill Companies., California .2012; P: 521-541.
25. Katzung BG. Masters SB, Trevor AJ. Basic and clinical pharmacology and therapeutic. McGraw â€“ Hill Companies, 11th ed. 2009; pp. 511.
26. Feighner Jp. Mechanism of action of antidepressant medication. J Clin Psychiatry.1999; 60(S4): 4-10.
27. Risch SC, Nemeroff CB. Neurochemical alteration of serotonergic neuronal system in depression. J Clin Psychiatry 1992; 53:3-7.
28. Zelman FP, Garver DL. Depression and antidepressant therapy receptor dynamics Prog Neuro Psychopharmacol Biol Psych 1990; 14:503-523.
29. Detke MJ, Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 1996; 73:43-46.
30. Payne GW, Neuman RS. Effects of hypomagnesia on histamine H1 receptor-mediated facilitation of NMDA responses. Br J Pharmacol, 1997; 121: 199â€“204.
31. Barbier A.J. And Bradbury M.J. Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders. CNS & Neurological Disorders - Drug Targets, 2007, 6, 31-43.
32. Leonard, BE. The role of noradrenaline in depression:a review . J Psychopharmacol.1997; 11: S39-S47.
33. Souza .DND, Zhang.F, Grazia. G, Battaglia and Van de kar . Fluoxetine-induced changers in body weight and 5HT receptor-mediated hormonal secretion in rats on tryptophan deficient diet. Am J Physiol Regul Intergr Com Physiol 2004; 286: R 390-397
34. Brunton. LL and Parker. KL. Goodman and Gillman. Manual of pharmacology and therapeutic. Copyright. McGraw â€“ Hill medical Companies, USA. 2008. pp. 282-297.
35. Yagiela AG, Jone FG, Dowed FJ, Johnson BS, Mariotti AJ, Neidle EA. Pharmacology and therapeutics for dentistry. American Dental Association. New-York 6th ed. 2011; P. 359- 371.
36. Cowen PJ. A rol for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990; 46: 43-51.
37. Guiard, B.P.; El Mansari, M.; Blier, P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr. Drug Targets 2009, 10, 1069-1084.